帕维拉治疗
PVLA
120.30
-7.04
-5.53%
帕维拉治疗
US · PVLA
#2822 按市值排名
上市于 1970
120.30
-7.04
-5.53%
实时 - 追踪5344个代码 - 心跳于10秒前
· 2026-10-16 20:02
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了1家。
- 机构持股总比例下降了1.4个百分点。
机构持股
- 机构持股比例
- 107.89% -1.36pp
- 机构数量
- 239 -1
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund62.89%
Hedge Fund19.98%
VC/PE Fund14.92%
Individual/Insider8.01%
Private Company4.26%
Public Company3.46%
Sovereign Wealth Fund1.85%
Government Pension Fund0.26%
Insurance Company0.22%
主要股东 截至 2026-06-30
Montanova Capital, LLC
7.88% · 1.14M 股
Jennison Associates LLC
6.67% · 960.62K 股
BlackRock
6.37% · 918.36K 股
Frazier Life Sciences Management, LP
6.12% · 882.40K 股
Wesley Kaupinen
5.73% · 825.82K 股
First Light Asset Management, LLC
5.36% · 771.90K 股
BVF Partners L.P.
4.67% · 672.79K 股
State Street Global Advisors
4.53% · 653.17K 股
T. Rowe Price Group, Inc.
4.43% · 638.87K 股
Vanguard Capital Management, LLC
4.08% · 587.79K 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 34次买入 · 15次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Wesley Kaupinen | Chief Executive Officer | 5.73% |
| George Jenkins | Chairperson | 1.11% |
| Todd Davis | Director | 0.78% |
| Elaine Heron | Director | 0.37% |
| Matthew Korenberg | Chief Financial Officer | 0.01% |
| Christopher Kiritsy | Independent Director | 0.00% |
| BVF Partners L.P. | -- | -- |
| Tadd Wessel | Director | -- |
| John Doux | Director | -- |
| Matthew Pauls | Director | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-15 | Kathleen Goin | Chief Operating Officer | Derivative Exercise and Sale | -4,302 | $7.14–153.24 |
| 2026-09-14 | George Jenkins | Chairperson | Automatic Disposition | -27,500 | $149.38–153.10 |
| 2026-09-10 | George Jenkins | Chairperson | Intent to Sell (Form 144) | -27,500 | $150.39 |
| 2026-09-01 | Christopher Kiritsy | Independent Director | Derivative Exercise and Sale | -313 | $127.20–157.00 |
| 2026-08-18 | Kathleen Goin | Chief Operating Officer | Derivative Exercise and Sale | -4,302 | $7.14–156.77 |
| 2026-07-14 | Kathleen Goin | Chief Operating Officer | Derivative Exercise and Sale | -4,302 | $7.14–150.25 |
| 2026-06-28 | Matthew Pauls | Director | Other Derivative Acquisition | +6,000 | $154.84 |
| 2026-06-16 | Kathleen Goin | Chief Operating Officer | Derivative Exercise and Sale | -4,302 | $7.14–112.23 |
| 2026-06-11 | Matthew Korenberg | Chief Financial Officer | Derivative Exercise and Retained | +1,000 | $13.60 |
| 2026-06-09 | George Jenkins | Chairperson | Other Derivative Acquisition | +3,000 | $102.19 |
| 2026-06-09 | Elaine Heron | Director | Other Derivative Acquisition | +3,000 | $102.19 |
| 2026-06-09 | Todd Davis | Director | Other Derivative Acquisition | +3,000 | $102.19 |
| 2026-06-09 | Christopher Kiritsy | Independent Director | Other Derivative Acquisition | +3,000 | $102.19 |
| 2026-06-09 | Tadd Wessel | Director | Other Derivative Acquisition | +3,000 | $102.19 |
| 2026-06-09 | John Doux | Director | Other Derivative Acquisition | +3,000 | $102.19 |
| 2026-05-19 | Kathleen Goin | Chief Operating Officer | Derivative Exercise and Sale | -4,302 | $7.14–111.90 |
| 2026-04-14 | Kathleen Goin | Chief Operating Officer | Derivative Exercise and Sale | -4,302 | $7.14–130.33 |
| 2026-04-12 | John Doux | Director | Other Derivative Acquisition | +6,000 | $129.00 |
| 2026-04-12 | John Doux | Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-29 | George Jenkins | Chairperson | Open Market Acquisition | +445 | $112.30 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 20:02:33 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
帕维拉治疗 讨论区 0 条评论